Status:

ENROLLING_BY_INVITATION

The BEACON Trial: Diagnostic Tools for Breast Lymphedema After Treatment for Breast Cancer

Lead Sponsor:

Massachusetts General Hospital

Conditions:

Breast Edema

Breast Lymphedema

Eligibility:

FEMALE

18+ years

Brief Summary

The goal of this observational study is to learn if participants agree to take part in the study, if the methods we are using for the study are feasible for the participants and the researchers, and t...

Detailed Description

The goal of this observational study is to learn if the study protocol is feasible, if we can accrue participants easily, and to determine how well two tools (tissue dielectric constant and ultrasound...

Eligibility Criteria

Inclusion

  • All participants must meet the following inclusion criteria:
  • Be a female between the ages of 18 and 85 years.
  • Have undergone breast conserving surgery +/- LN removal (sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)
  • Have no residual cancer in the breast after definitive breast surgery
  • Have been treated with radiation therapy and have completed breast cancer treatment (excluding Herceptin and hormonal treatments) at MGH greater than or equal to 3 months ago.
  • Be able to read and understand English
  • Understand the proposed study and be willing and fully able to comply with the study procedures
  • Be a willing participant and be capable of giving and has given informed written consent for entry into the study
  • EXCLUSION CRITERIA
  • Participants will be excluded if they:
  • Have bilateral BC
  • Have metastatic or inflammatory BC
  • Will be excluded from the SOZO measurement of the study if they have implanted cardiac devices or neurostimulators
  • Have any medical condition that may result in breast swelling;
  • Uncontrolled congestive cardiac failure,
  • Arteriovenous haemodialysis,
  • Current infection or cellulitis of either breast.
  • Be pregnant or currently breast feeding.
  • Have a known over-active thyroid or known benign thyroid tumour

Exclusion

    Key Trial Info

    Start Date :

    May 5 2025

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2027

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT06900023

    Start Date

    May 5 2025

    End Date

    December 1 2027

    Last Update

    July 16 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Massachusetts General Hospital

    Boston, Massachusetts, United States, 02114